Vietnam Healthcare Outlook: Government Spurs Foreign Investment

KUALA LUMPUR, Malaysia, Aug. 12, 2015 /PRNewswire/ -- The healthcare market in Vietnam is poised to become a significant medical hub in the Asia-Pacific region as the government carefully opens its arms to foreign assistance. With state-owned generic drug manufacturers undergoing privatisation or launching initial public offerings (IPOs), the country will soon be a centralised spot for generic pharmaceutical manufacturing.

New analysis from Frost & Sullivan, Vietnam Healthcare Outlook (https://www.frost.com/p887), finds that market expenditure stood at US$12.90 billion in 2014 and estimates this to reach US$27.48 billion in 2020 at a compound annual growth rate of 13.4 percent.

"The deployment of the universal health coverage scheme has escalated demand for healthcare services in Vietnam," said Frost & Sullivan Healthcare Research Analyst Philip Tay. "The program is swinging public health expenditure towards low-cost, centralised purchases, thus shifting preference to affordable generics over branded drugs, and basic medical devices instead of high-end technology."

While the government in Vietnam favours local manufacturing, it is also working with global pharmaceutical players to create a solution that will benefit both parties and push the market ahead. For instance, the government has provided tax exemption for the import of medical device components. However, regulatory bodies are still in the development phase, and hence, import and distribution practices remain grey areas. Fragmented distribution and lack of advanced infrastructure also limit market development.

Holding discussions with pharmaceutical firms through associations and representatives will help the government make informed choices, understand implications on investors, and prime the healthcare market for further growth. Analysing case studies of works and systems that have worked in other nations will aid the country in designing a stable regulatory environment with investor interests assured.

"In this protected domain, global providers must seek out partnerships and joint ventures to establish a solid footing," suggested Tay. "Collaboration with distributors and even local manufacturers will grant quick access to infrastructure and know-how, offering a firm standing against the ebbs and flows of the dynamic Vietnamese healthcare market."

Vietnam Healthcare Outlook is part of the Advanced Medical Technologies (http://www.medtech.frost.com) Growth Partnership Service program. Frost & Sullivan's related studies include: Asia-Pacific Healthcare Industry Outlook, Indonesia Healthcare Outlook, and Healthcare IT Spending in Australia. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.